



Uloric[®] (febuxostat) – New warning

- On February 6, 2018, the FDA approved an update to the *Warnings and Precautions* section of the [Uloric \(febuxostat\)](#) drug label regarding serious skin reactions.
- Uloric is approved for the chronic management of hyperuricemia in patients with gout.
 - Uloric is not recommended for the treatment of asymptomatic hyperuricemia.
- Post marketing reports of serious skin and hypersensitivity reactions, including Stevens-Johnson Syndrome, drug reaction with eosinophilia and systemic symptoms and toxic epidermal necrolysis have been reported in patients taking Uloric.
 - Discontinue Uloric if serious skin reactions are suspected.
 - Many of these patients had reported previous similar skin reactions to [allopurinol](#). Uloric should be used with caution in these patients.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.